TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock News

USA - NYSE:TEVA - US8816242098 - ADR

24.28 USD

-0.16 (-0.65%)

Last: 11/20/2025, 8:04:00 PM

24.44 USD

+0.16 (+0.66%)

After Hours: 11/20/2025, 8:04:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TEVA Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Benzinga - Mentions: GOOG

Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report

2 days ago - By: Teva Pharmaceutical Industries Ltd

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

6 days ago - By: Benzinga - Mentions: STUB APP AMZN INSM ...

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves

7 days ago - By: Zacks Investment Research - Mentions: ANIP AMRX VTRS

ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?

16 days ago - By: Investor's Business Daily

Teva Pharma Surges On Its Big Sales Beat, Austedo Guidance Hike

7 days ago - By: Zacks Investment Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

10 days ago - By: The Motley Fool - Mentions: NVDA PLTR

Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023

10 days ago - By: Zacks Investment Research

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

13 days ago - By: Teva Pharmaceutical Industries Ltd

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

13 days ago - By: Teva Pharmaceutical Industries Ltd

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

13 days ago - By: Zacks Investment Research - Mentions: BWAY

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?

14 days ago - By: Zacks Investment Research - Mentions: ANIP SNDX ARQT

TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up

15 days ago - By: The Motley Fool

Why Teva Pharmaceutical Stock Rocked the Market Today

16 days ago - By: Zacks Investment Research

Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings

16 days ago - By: Teva Pharmaceutical Industries Ltd

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

16 days ago - By: Teva Pharmaceutical Industries Ltd

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

17 days ago - By: Zacks Investment Research

Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

18 days ago - By: Teva Pharmaceutical Industries Ltd

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

20 days ago - By: Teva Pharmaceutical Industries Ltd

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

20 days ago - By: Teva Pharmaceutical Industries Ltd

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva und Prestige Biopharma schließen Lizenzvereinbarung für die Vermarktung von Tuznue® in Europa

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva et Prestige Biopharma concluent un accord de licence pour la commercialisation de Tuznue® en Europe

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

a month ago - By: Zacks Investment Research - Mentions: SNY ALLO CMMB

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

a month ago - By: Teva Pharmaceutical Industries Ltd

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder